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Aims Idiopathic atrial fibrillation (AF) may be an expression of as yet undetected underlying heart disease. We found it




Forty-one consecutive idiopathic AF patients (56+ 10 years, 66% male) were compared with 45 healthy control
patients in permanent sinus rhythm. Patients were free of hypertension, antihypertensive and antiarrhythmic
drugs, diabetes, congestive heart failure, coronary artery or peripheral vascular disease, previous stroke, thyroid, pul-
monary and renal disease, and structural abnormalities on echocardiography. Baseline characteristics and echocardio-
graphic parameters were equal in AF cases and controls. During a mean follow-up of 66+11 months, CVD occurred
significantly more often in idiopathic AF patients compared with controls (49 vs. 20%, P ¼ 0.006). Patients with idio-
pathic AF were significantly younger at the time of their first CV event compared with controls (59+9 vs. 64+5
years, P ¼ 0.027), and had more severe disease. Multivariable Cox regression analysis revealed that age, a history of
AF, and echocardiographic left ventricular wall width were significant predictors of CVD development.
Conclusion Patients originally diagnosed with idiopathic AF develop CVD more often, at younger age, and with a more severe
disease profile compared with healthy sinus rhythm control patients. The detection and treatment of CVD in an early
stage could improve the prognosis of these patients. At present it seems prudent to regularly check idiopathic AF
patients for the insidious development of CVD.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Introduction
Idiopathic atrial fibrillation (AF) refers to the occurrence of the ar-
rhythmia in the absence of a cardiovascular or pulmonary disease
generating the pathophysiological substrate for the arrhythmia.
Follow-up data in patients diagnosed with idiopathic AF are
sparse and mainly based on two large observational population
studies.1– 3
Data from the Olmsted County database suggest that idiopathic
AF is a benign disease with comparable risk of thromboembolism,
congestive heart failure, and mortality as the general population. In
contrast, data from the Framingham Heart Study and the Paris
Prospective Study show that idiopathic AF is associated with
increased mortality and co-morbidity.1 – 4 Presumably, differences
regarding the definition of idiopathic AF in these studies are the
main cause of these ambivalent results. Translating the data of
these studies into daily clinical practice is not easily established
due to the long follow-up duration (mean of 23 years), and the
focus on the occurrence of major adverse cardiovascular and cere-
brovascular events [MACCE: death, stroke/transient ischaemic
attack (TIA), myocardial infarction, embolism, or major bleeding]
instead of cardiovascular disease (CVD) itself. More recent obser-
vational studies show that ageing, development of CVD, and
* Corresponding author. Tel: +31 43 387 5093; fax: +31 4338 751 04, Email: b.weijs@mumc.nl
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increased left atrial (LA) volume relate to long-term prognosis of
idiopathic AF patients.2,5,6
The detection and treatment of CVD in an early stage could
improve the prognosis of these patients. Since idiopathic AF may
be an expression of as yet undetected underlying heart disease,
we found it useful for clinical practice to study the development
of CVD over time in patients diagnosed with idiopathic AF.
Methods
Study population
We prospectively studied 41 consecutive idiopathic AF patients and 45
healthy sinus rhythm control patients, who were referred to the out-
patient clinic of one of our cardiologists (RGT) between 2004 and
2007 for a standard transthoracic echocardiographic examination (in
the work up for AF or for cardiovascular screening purpose in the
sinus rhythm control patients). The study was approved by the local
Ethics Committee and complied with the declaration of Helsinki.
Informed consent of all patients was obtained.
Atrial fibrillation patients had to be in AF at time of enrolment or
had a previous documented history of paroxysmal or persistent AF
defined as a documented episode of AF lasting 30 s or more. Idiopathic
AF and healthy sinus rhythm were strictly defined as the absence of
any CVD including hypertension [no antihypertensive drug use (diure-
tics, angiotensin-converting enzyme inhibitors, aldosterone receptor
blockers, aldosterone receptor antagonists, non-dihydropyridine
calcium antagonists, other), all previously recorded systolic blood pres-
sures not exceeding 140 mmHg, diastolic blood pressures not exceeding
90 mmHg, and absence of left ventricular hypertrophy (interventricular
septum width .10 mm, posterior wall width .10 mm)], diabetes
(fasting blood glucose .7.0 mmol/L), or hypercholesterolaemia (total
fasting cholesterol .6.4 mmol/L and no statin use). In addition, no cor-
onary artery disease (i.e. absence of typical exercise-related angina pec-
toris, an exercise stress test with significant ST-segment depression,
previous acute coronary syndrome, percutaneous or surgical coronary
revascularization, or previous angiographically documented coronary
disease), no peripheral vascular disease (intermittent claudication, or
previous percutaneous or surgical revascularization), no congestive
heart failure (no clinical signs or symptoms, left ventricular ejection frac-
tion .50%, normal diastolic function parameters), no previous stroke,
no thyroid or pulmonary disease, no significant renal dysfunction (esti-
mated MDRD7 glomerular filtration rate ,60 mL/min), no malignancy,
and no evidence for structural CVD on echocardiography including
valvular heart disease.
During follow-up we collected all emerging CVDs, including cardio-
vascular death, thromboembolic complications (stroke, TIA), congest-
ive heart failure, coronary artery disease (acute coronary syndrome,
percutaneous or surgical coronary revascularization, or angiographi-
cally documented coronary disease with angina pectoris), and new
onset hypertension [antihypertensive drug use (diuretics, angiotensin-
converting enzyme inhibitors, angiotensin II receptor antagonists, al-
dosterone receptor antagonists, dihydropyridine calcium-channel
blockers), systolic blood pressures exceeding 140 mmHg, diastolic
blood pressures exceeding 90 mmHg, or development of left ventricu-
lar hypertrophy (interventricular septum width ≥10 mm, posterior
wall width ≥10 mm, according to the American Society of
Echocardiography-convention) during follow-up echocardiography].
The electrocardiogram
At the time of inclusion and during follow-up, all patients underwent
12-lead electrocardiographic (ECG) recording obtained in the
supine position (MAC 5000, Marquette Medical Systems, Milwaukee,
WI, USA).
Echocardiographic examination
The echocardiographic examination consisted of a standard two-
dimensional echocardiogram, including M-mode and Doppler echocar-
diography (Sonos 5500, Philips Medical Systems, Andover, MS, USA)
during continuous ECG monitoring according to the recommendations
as described in the American Society of Echocardiography guidelines.
After we obtained baseline echocardiographic data, all measurements
for study purposes were made by an independent observer who was
blinded for arrhythmia history and other patient characteristics.
Echocardiography during follow-up was left at the discretion of the
treating physician.
Data collection
Patient characteristics, including medication, (arrhythmia) history,
ECGs, visits to cardiac emergency department, hospital admissions,
and major cardiovascular events at the time of echocardiography and
during follow-up were obtained and cross-checked by two independ-
ent observers. Data were derived from the patient charts (both hos-
pital and general practitioner), electronic medical records and the
electronic ECG database, which stores all ECGs and Holter record-
ings, performed in our hospital. Progression of AF was defined as
follows: development of new-onset AF during follow-up in control
patients or paroxysmal AF at baseline becoming persistent or perman-
ent AF during follow-up. Since the Maastricht University Medical
Centre has a strong regional community care function, none of the
patients were lost to follow-up. At the end of follow-up, general prac-
titioners were contacted in order to obtain additional follow-up data.
Statistical analysis
Continuous variables are expressed as mean and standard deviation;
categorical variables are expressed as absolute numbers and
percentages.
Baseline variables were compared with an independent T-test (two-
tailed) after performing Levene’s test for equality of variances in all
normally distributed continuous variables and Mann–Whitney test
(two-tailed) in all not normally distributed variables. Categorical vari-
ables were tested with two-sided Fisher’s exact test.
All parameters showing a significant Cox regression univariate rela-
tion with the occurrence of CVD during follow-up (age, AF history,
What’s new?
† Idiopathic AF is often described as a benign disease; this
study shows that in clinical practice almost half of the patients
originally diagnosed with idiopathic AF develops CVD within
merely 5 years follow-up.
† Cardiovascular disease develops not only more often, but
also at younger age and with a more severe disease
profile in idiopathic AF patients compared with healthy
sinus rhythm controls.
† Patients who developed CVD during follow-up more often
showed an increase in atrial size over time compared with
patients who did not develop CVD.
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posterior wall width) were included as covariates in a Cox regression
model (retention level set at 0.1), odds ratios and 95% confidence
intervals were calculated and results were checked for colinearity
(off note, Vitamin K antagonist (VKA) use and interventricular
septum width were not included since these are directly related to re-
spectively AF history and posterior wall width).
Statistical analysis was performed with SPSS statistical software
(SPSS, Inc. release 18.0) and statistical significance was assumed for
P , 0.05.
Results
The overall mean (SD) age was 54 (11) years and just over half of
patients was male (58%). Baseline characteristics, ECG, and stand-
ard echocardiographic parameters were equal in AF cases and con-
trols (Table 1). Particularly, mean+ SD age (56+ 10 vs. 53+ 12
years, P ¼ 0.465), P-wave duration (88+ 20 vs. 86+17 ms, P ¼
0.521) and LA diameter (39+5 vs. 38+ 4 mm, P ¼ 0.254) did
not differ between AF patients and controls. A few sinus rhythm
patients were on aspirin or a beta-blocker because their referring
physician deemed these drugs necessary due to the suspicion of
CVD (not found at enrolment after full work-up including echocar-
diography). A total of 14 (34%) AF patients used oral anticoagula-
tion despite low cardiovascular risk profile. Atrial fibrillation
duration showed a statistically significant but weak correlation to
LA size (Spearman’s correlation coefficient: 0.365, P ¼ 0.024).
Follow-up was completed in all patients; mean follow-up dur-
ation was 66+11 months (Table 2). Cardiovascular disease oc-
curred significantly more often in idiopathic AF patients compared
with sinus rhythm controls (49 vs. 20%, P ¼ 0.006). The Kaplan–
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Baseline characteristics in patients with sinus












57 (46–62) 58 (46–64) 0.465a
Male 23 (51) 27 (66) 0.194b
Body mass index
(kg/m2)






Oral anticoagulation 0 14 (34) ,0.001b
Aspirin 5 (11) 18 (44) 0.001b
Beta-blocker 7 (16) 13 (32) 0.124b
ECG
Heart rate (b.p.m.) 70 (12) 66 (11) 0.176c
P-wave duration (ms) 86 (17) 88 (20) 0.521c
PQ duration (ms) 153 (29) 158 (24) 0.304c
QRS duration (ms) 93 (17) 93 (11) 0.987c
QTc duration (ms) 411 (19) 410 (18) 0.820c
Echocardiography
Aorta diameter (mm) 33 (3) 34 (4) 0.056c
Left atrial diameter
(mm)




48 (4) 49 (4) 0.191c
Left ventricular end
systolic diameter (mm)
32 (4) 33 (3) 0.261c
Interventricular septum
width (mm)
8.7 (0.9) 8.6 (0.8) 0.763a
Posterior wall width
(mm)
8.4 (0.8) 8.5 (0.7) 0.693a
Left ventricular ejection
fraction (%)
62 (5) 62 (4) 0.976c
Data are presented as mean (+SD) or n (%) unless otherwise specified.
aNon-normal distribution, Mann–Whitney U test.
bCategorical data, Fisher’s exact test.
cNormal distribution, Levene’s independent samples T-test.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Atrial fibrillation progression, cardiovascular











2 (4) 6 (15) 0.144c
Visits cardiac emergency
department
2 (4) 21 (66) ,0.001c
Cardiovascular (related)
disease in follow-upa
9 (20) 20 (49) 0.006c
Cardiovascular death 0 1 (3) 1.0c
Myocardial infarction 0 1 (3) 1.0c
Cerebrovascular
accident
0 2 (5) 0.218c
Congestive heart failure 0 3 (8) 0.100c
Coronary artery disease 4 (9) 5 (12) 0.299c
New onset
hypertension
7 (16) 12 (30) 0.191c
Medication
Oral anticoagulation 1 (2) 18 (45) ,0.001c
Aspirin 10 (22) 15 (38) 0.231c
Beta-blocker 5 (12) 12 (30) 0.058c
Statins 7 (16) 7 (18) 1.000c
Antihypertensive drug
useb
7 (16) 12 (30) 0.191c
Data are presented as mean (+SD) or n (%).
aThe tabulations of cardiovascular diseases during follow-up include the first event
for each patient.
bACE-inhibitor, angiotensin receptor blocker, diuretics, calcium channel blocker.
cCategorical data, Fisher’s exact test.








aastricht user on 27 Septem
ber 2021
Meier 6-year cumulative risk for occurrence of CVD was significantly
increased for patients with idiopathic AF (Figure 1).
Three patients (7%) with idiopathic AF died (one due to myo-
cardial infarction, one due to malignancy, and the other developed
a cerebrovascular accident and died later in follow-up due to ma-
lignancy), whereas none of the control patients died during follow-
up. Hypertension (33 vs. 16%, P ¼ 0.123) and coronary artery
disease (12 vs. 9%, P ¼ 0.299) developed most frequently. Patients
with idiopathic AF were significantly younger at the time of cardio-
vascular event or associated disease (59+9 vs. 64+5 years, P ¼
0.027) and had developed a more severe disease profile compared
with controls (Figure 2).
Echocardiography during follow-up was available in 34 patients
(20 AF, 14 controls). Left atrial diameter increased in 23 patients
[AF: 15 (75%) vs. SR: 8 (57%), P ¼ 0.485] with a mean increase
of 3.0+ 4 mm in patients with idiopathic AF vs. 0.8+3 mm in
controls (P ¼ 0.099). Patients who developed CVD during follow-
up more often showed an increase in atrial size compared with
patients who did not develop CVD [17 (90%) vs. 6 (40%), P ¼
0.003] (Figure 3).
The following baseline parameters showed a significant Cox re-
gression univariate relation with the occurrence of CVD during
follow-up: age, AF history, VKA use, interventricular septum
width, and posterior wall width (Table 3). Multivariable Cox regres-
sion analysis revealed that age, a history of AF, and posterior wall
width were predictors of CVD development (Table 4).
Discussion
This study is one of the few following idiopathic AF patients for the
development of CVD in general instead of focusing on major
cardio- and cerebrovascular events only, and comparing them
with patients in sinus rhythm without a cardiovascular diagnosis.
It shows that in clinical practice almost half of the patients originally
diagnosed with idiopathic AF develops CVD within merely 5 years
follow-up. Cardiovascular disease develops more often, at younger
age and with a more severe disease profile, in these patients com-
pared with healthy sinus rhythm controls. This suggests that idio-
pathic AF is an expression of as yet undetected underlying CVD
and that these patients should be checked regularly for the devel-
opment of CVD.
Longitudinal studies on idiopathic AF are rare and the definitions
used in these studies are mostly not identical and often lenient.
The presence of arterial hypertension for instance was not an ex-
clusion criterion in the Framingham Heart study on idiopathic atrial
fibrillation.1 We used a very strict definition for idiopathic AF so
riskwise, all patients were at low risk and similar at the outset.
Yet, almost half of the patients with idiopathic AF developed
CVD or MACCE. This suggests that not only advanced AF but
also idiopathic AF is associated with CVD and events. To what
extent AF on itself contributes is difficult to say. With increased
Figure 1 Kaplan–Meier cumulative incidence of the occur-
rence of first cardiovascular disease in patients with idiopathic
atrial fibrillation and healthy control patients in permanent sinus
rhythm (log rank P ¼ 0.001).
Figure 2 Occurrence and severity of cardiovascular disease in
follow-up per patient and according to age in patients with idio-
pathic atrial fibrillation and healthy control patients in permanent
sinus rhythm. Minor cardiovascular disease: arterial hypertension
(AHT), coronary artery disease (CAD); Major CVD: congestive
heart failure (CHF), cerebrovascular accident (CVA), myocardial
infarction (MI), death.
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levels of thrombogenesis and uncontrolled heart rate, AF could act
as a mechanism in the development of stroke and congestive heart
failure.8 –11 But it is difficult to find a similar role for AF in the de-
velopment of arterial hypertension (i.e. AF may induce hyperten-
sion through concealed insidious adrenergic activation due to
high heart rates) or coronary artery disease.12,13 In these cases,
AF could be seen as a whistleblower of as yet undetected, clinically
concealed coronary artery disease, or arterial hypertension.
Arterial hypertension is a major risk factor for the development
of AF and cardiovascular events but is often not recognized. This
so called masked or latent hypertension has been described in
patients initially diagnosed with idiopathic AF.14,15 Although
patients with hypertension or left ventricular hypertrophy were
excluded in the present study, posterior wall width—although
within normal limits—was a predictor of CVD. This might
suggest the presence of masked hypertension or pre-hypertension
(systolic blood pressure of 120–139 mmHg and diastolic blood
pressure of 80–89 mmHg) in patients participating in this study.
It also suggests that even normal wall sizes show a variation repre-
senting preclinical disease once wall width is found to be at the
high end of normal. These patients seem to be at an increased
risk of developing CVD or AF compared with those with normal
blood pressure levels.16– 19 The present study corroborates the
findings by Katritsis et al., supporting the notion that hypertension
may develop or become apparent in many idiopathic AF patients
(30% during 5-year follow-up) and emphasizes the importance of
regular 24 h ambulatory blood pressure monitoring and adequate
treatment of early hypertension in patients with idiopathic AF since
it relates to their vascular prognosis.
Many clinical parameters are only indirectly related to AF.
However, the true ‘scene of calamity’ are the atria. Increased LA
size is associated with increased risk of AF onset and recurrence,
other CVD and mortality.6,20
In this study, LA sizes at the outset were equal between patients
with and without AF and were not related to the occurrence of
CVD in the overall population. On the other hand, patients with
LA increase during follow-up were prone to develop CVD.
These results confirm previous findings during three decades
follow-up in idiopathic AF patients.6
Figure 3 Left atrial diameters during follow-up according to
the occurrence of cardiovascular events in 20 atrial fibrillation
patients and 14 sinus rhythm control patients.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Baseline characteristics in patients who did not








Age 52 (12) 59 (8) 0.003a
Male 31 (54) 19 (66) 0.363b
Body mass index (kg/m2) 25 (4) 28 (4) 0.172c
Atrial fibrillation in
history
21 (37) 20 (69) 0.005b
Follow-up duration
(months)
67 (11) 65 (10) 0.609a
Medication
Oral anticoagulation 5 (9) 9 (31) 0.013b
Aspirin 15 (26) 8 (28) 1.0b
Beta-blocker 13 (23) 7 (24) 1.0b
Echocardiography
Aorta diameter (mm) 33 (3) 34 (4) 0.168c
Left atrial diameter (mm) 38 (4) 41 (4) 0.447c
Left atrial volume (cc) 51 (17) 57 (17) 0.744c
Left ventricular end
diastolic diameter (mm)
48 (4) 50 (5) 0.402c
Left ventricular end
systolic diameter (mm)
32 (3) 34 (4) 0.109c
Interventricular septum
width (mm)
8.4 (0.8) 9.0 (0.9) 0.006a
Posterior wall width
(mm)
8.3 (0.6) 8.8 (0.8) 0.005a
Left ventricular ejection
fraction (%)
63 (4) 61 (5) 0.294c
Data are presented as mean (+SD) or n (%).
aNon-normal distribution, Mann–Whitney U test.
bCategorical data, Fisher’s exact test.
cNormal distribution, Levene’s independent samples T-test.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Multivariable Cox regression analysis:
demographic and clinical variables related to
occurrence of cardiovascular disease
OR 95% CI P
History of AF 3.265 1.470–7.250 0.004
Posterior wall width (mm) 1.993 1.249–3.181 0.004
Age (years) 1.059 1.013–1.106 0.010
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Idiopathic AF is often described as a benign disease.3,21
However, our data suggests that not every idiopathic AF patient
has the same cardiovascular prognosis. It seems that patients
with idiopathic AF can be divided into two groups following diver-
gent courses regarding CVD development. Those who are at true
low risk on one hand, and those with deterioration of CVD in the
years after idiopathic AF diagnosis as reflected by AF progression,
development of CVD and events. This study shows that within 5
years follow-up almost 50% of the patients initially suffering from
idiopathic AF develops CVD. During long-term follow-up in the
Olmsted County population, the same number of those with idio-
pathic AF (50%) developed major adverse cardiovascular events.6
It is plausible that the patients in our study are the same as the
patients in the Olmsted County cohort but caught somewhat
later in their vascular career. Apparently, it is possible to identify
these patients since they have in common that atrial size appears
to increase during follow-up. At present, it seems judicious to
closely follow these patients at the outpatient department for
the development of CVD. Repeated blood pressure measurements
and echocardiography (including LA size and posterior wall width)
seem prudent in patients with idiopathic AF.
Limitations
The study result was obtained in a relatively small and—by its
nature—highly selected population and should be reproduced in
other cohorts. Nevertheless, it seems reasonable to state that a
substantial part of patients originally diagnosed with idiopathic
AF develop CVD during short-term follow-up. Since sinus
rhythm patients were referred for cardiovascular screening pur-
poses rather than AF, referral bias may have played a role but
would—if anything—have led to a higher incidence of events in
the control population rather than the reverse. Although we me-
ticulously tried to rule out hypertension, specific cases of
masked hypertension could be missed since 24 h ambulatory
blood pressure monitoring was not performed. Follow-up echo-
cardiography was not available in all patients. As a result, potential
surveillance bias due to echocardiography being performed for
renewed suspicion or actual development of cardiac disease
could not be excluded. However, this bias holds for both groups
and, in addition, does not invalidate the relationship between
size increase and disease development.
Conclusion
Patients originally diagnosed with idiopathic AF develop CVD
more often, earlier in time and at younger age compared with
healthy sinus rhythm control patients. Age, history of AF, and pos-
terior wall width are significant predictors of CVD development.
The detection and treatment of CVD in an early stage could
improve the prognosis of these patients. At present it seems
prudent to regularly check idiopathic AF patients for the develop-
ment of CV disease.
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